Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

Compare

1,071 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TSHA Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Taysha

Gene Therapies

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TSHA Stock 12 Month Forecast

Average Price Target

$8.21

▲(182.13% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $8.21 with a high forecast of $14.00 and a low forecast of $2.50. The average price target represents a 182.13% change from the last price of $2.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.63,3.5046153846153847,4.3792307692307695,5.253846153846154,6.128461538461538,7.003076923076923,7.877692307692308,8.752307692307692,9.626923076923077,10.501538461538463,11.376153846153848,12.250769230769233,13.125384615384615,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.63,3.059230769230769,3.4884615384615385,3.917692307692308,4.346923076923077,4.776153846153846,5.205384615384616,5.634615384615385,6.063846153846154,6.493076923076924,6.922307692307693,7.351538461538462,7.7807692307692315,{"y":8.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.63,2.62,2.61,2.6,2.59,2.58,2.57,2.56,2.55,2.54,2.53,2.52,2.51,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$8.21

Lowest Price Target$2.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Whitney Ijem

Canaccord Genuity

$11→$14

Buy

381.10%

Upside

Reiterated

08/13/25

Positive Outlook for Taysha Gene Therapies: Buy Rating Reinforced by Strong Financial Position and Promising Clinical Progress

Yanan Zhu

Wells Fargo

$7.5→$8

Buy

174.91%

Upside

Reiterated

08/13/25

Wells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

Geulah Livshits

Chardan Capital

$9→$10

Buy

243.64%

Upside

Reiterated

08/12/25

Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)TSHA (Buy, PT to $10): 2Q25 Results; Pivotal REVEAL Enrollment to Start in 4Q – The resulting changes shift our PT to $10.

Gil Blum

Needham

Buy

174.91%

Upside

Reiterated

08/12/25

Taysha Gene Therapies: Positive Outlook with Pivotal Study and Strong Financial Health Justifies Buy RatingWe consider the study relatively de-risked, given its favorable design (note) and strong clinical data from Part A of REVEAL, showing all 10 patients would have met response criteria. We maintain our Buy Rating and our $8 Price Target.

Tazeen Ahmad

Bank of America Securities

Buy

174.91%

Upside

Initiated

07/11/25

Taysha Gene Therapies initiated with a Buy at BofATaysha Gene Therapies initiated with a Buy at BofA

Dex Genotek

TR | OpenAI - 4o

$2.5

Hold

-14.09%

Downside

Reiterated

07/09/25

Joon Lee

Truist Financial

―

Buy

―

Reiterated

07/01/25

Truist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

Biren Amin

Piper Sandler

Buy

209.28%

Upside

Reiterated

07/01/25

Piper Sandler Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

Evan Seigerman

BMO Capital

Buy

71.82%

Upside

Reiterated

06/12/25

IRSF Conference: More to Be REVEALED? Additional Data Highlights Benefits

Kristen Kluska

Cantor Fitzgerald

$7→$13

Buy

346.74%

Upside

Reiterated

06/11/25

Taysha Gene Therapies price target raised to $13 from $7 at Cantor FitzgeraldTaysha Gene Therapies price target raised to $13 from $7 at Cantor Fitzgerald

Maury Raycroft

Jefferies

Buy

174.91%

Upside

Reiterated

06/11/25

Promising Potential of Taysha Gene Therapies: Buy Rating Affirmed by Maury Raycroft

Silvan Tuerkcan

Citizens JMP

$5→$6

Buy

106.19%

Upside

Reiterated

05/29/25

Citizens JMP Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

Jack Allen

Robert W. Baird

Buy

140.55%

Upside

Reiterated

05/15/25

Baird reiterates Outperform Rating on Taysha Gene Therapies (TSHA); Encouraged by FDA InteractionsBaird analyst Jack Allen reiterated an Outperform rating and $7.00 price target on Taysha Gene Therapies (NASDAQ: TSHA) saying they are incrementally positive on regulatory update disclosed concurrent with earnings.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Whitney Ijem

Canaccord Genuity

$11→$14

Buy

381.10%

Upside

Reiterated

08/13/25

Positive Outlook for Taysha Gene Therapies: Buy Rating Reinforced by Strong Financial Position and Promising Clinical Progress

Yanan Zhu

Wells Fargo

$7.5→$8

Buy

174.91%

Upside

Reiterated

08/13/25

Wells Fargo Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

Geulah Livshits

Chardan Capital

$9→$10

Buy

243.64%

Upside

Reiterated

08/12/25

Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)TSHA (Buy, PT to $10): 2Q25 Results; Pivotal REVEAL Enrollment to Start in 4Q – The resulting changes shift our PT to $10.

Gil Blum

Needham

Buy

174.91%

Upside

Reiterated

08/12/25

Tazeen Ahmad

Bank of America Securities

Buy

174.91%

Upside

Initiated

07/11/25

Taysha Gene Therapies initiated with a Buy at BofATaysha Gene Therapies initiated with a Buy at BofA

Dex Genotek

TR | OpenAI - 4o

$2.5

Hold

-14.09%

Downside

Reiterated

07/09/25

Joon Lee

Truist Financial

―

Buy

―

Reiterated

07/01/25

Truist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

Biren Amin

Piper Sandler

Buy

209.28%

Upside

Reiterated

07/01/25

Piper Sandler Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

Evan Seigerman

BMO Capital

Buy

71.82%

Upside

Reiterated

06/12/25

IRSF Conference: More to Be REVEALED? Additional Data Highlights Benefits

Kristen Kluska

Cantor Fitzgerald

$7→$13

Buy

346.74%

Upside

Reiterated

06/11/25

Taysha Gene Therapies price target raised to $13 from $7 at Cantor FitzgeraldTaysha Gene Therapies price target raised to $13 from $7 at Cantor Fitzgerald

Maury Raycroft

Jefferies

Buy

174.91%

Upside

Reiterated

06/11/25

Promising Potential of Taysha Gene Therapies: Buy Rating Affirmed by Maury Raycroft

Silvan Tuerkcan

Citizens JMP

$5→$6

Buy

106.19%

Upside

Reiterated

05/29/25

Citizens JMP Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

Jack Allen

Robert W. Baird

Buy

140.55%

Upside

Reiterated

05/15/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Taysha Gene Therapies

1 Month

xxx

Success Rate

7/15 ratings generated profit

Average Return

+3.43%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +3.43% per trade.

3 Months

xxx

Success Rate

8/19 ratings generated profit

Average Return

-0.97%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -0.97% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

12/19 ratings generated profit

Average Return

+32.06%

reiterated a buy rating last month

Copying Joon Lee's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +32.06% per trade.

2 Years

xxx

Success Rate

12/19 ratings generated profit

Average Return

+25.74%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.16% of your transactions generating a profit, with an average return of +25.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TSHA Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TSHA has received 18 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TSHA average Analyst price target in the past 3 months is 8.21.

Each month's total comprises the sum of three months' worth of ratings.

TSHA Financial Forecast

TSHA Earnings Forecast

Next quarter’s earnings estimate for TSHA is -$0.09 with a range of -$0.11 to -$0.07. The previous quarter’s EPS was -$0.09. TSHA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.70% of the time in the same period. In the last calendar year TSHA has Preformed in-line its overall industry.

TSHA Sales Forecast

Next quarter’s sales forecast for TSHA is $1.55M with a range of $0.00 to $3.80M. The previous quarter’s sales results were $1.99M. TSHA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.46% of the time in the same period. In the last calendar year TSHA has Preformed in-line its overall industry.

TSHA Stock Forecast FAQ

What is TSHA’s average 12-month price target, according to analysts?

Based on analyst ratings, Taysha Gene Therapies’s 12-month average price target is 8.21.

What is TSHA’s upside potential, based on the analysts’ average price target?

Taysha Gene Therapies has 182.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TSHA a Buy, Sell or Hold?

Taysha Gene Therapies has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Taysha Gene Therapies’s price target?

The average price target for Taysha Gene Therapies is 8.21. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $2.50. The average price target represents 182.13% Increase from the current price of $2.91.

What do analysts say about Taysha Gene Therapies?

Taysha Gene Therapies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of TSHA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

TSHA Analyst Ratings

TSHA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Taysha Gene Therapies

TSHA Analyst Recommendation Trends

TSHA Financial Forecast

TSHA Earnings Forecast

TSHA Sales Forecast

TSHA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts